14th Dec 2021 22:01
Okyo Pharma Ltd - London-headquartered biotechnology company - Says patent entitled "Methods of Lowering Blink Reflex for the Treatment of Dry Eye Disease" has been issued by the US Patent & Trademark Office as US Patent Number 11,197,906. The drug, planned to be administered topically, is anticipated to open human studies with a Phase 2 clinical trial in dry eye disease patients in the fourth quarter of 2022.
"We have made significant progress with our pre-IND work on OK-101 and are planning to file the IND to treat DED in Q3 2022, followed by the commencement of a Phase 2 trial in DED patients in Q4 2022," says Chief Executive Officer Gary S. Jacob. "We believe that OK-101 can provide a new way to treat DED patients who are presently not well served by drugs presently approved for treating dry eye disease."
Current stock price: 7.20 pence
Year-to-date change: down 5.6%
By Arvind Bhunjun; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
OKYO.L